Acorda regains licensing rights of high-quality MS drug Fampyra from Biogen
USA – Acorda Therapeutics has regained the licensing rights for multiple sclerosis (MS) drug,...
Read More
Tag: Biogen
US FDA gives nod to first and only oral treatment for Postpartum Depression
USA – The United States Food and Drug Administration (FDA), has approved Biogen’s and Sage...
Read More
Biogen finalizes deal to acquire Reata Pharmaceuticals for US$7.3B
USA—Biogen Inc. and Reata Pharmaceuticals, Inc., have announced that they have reached a...
Read More
Biogen announces job cuts and shifts focus to new Alzheimer’s drug amidst challenging times
USA —In a bid to navigate turbulent waters and reignite growth, Biogen Inc, a U.S. drugmaker, is...
Read More
FDA grants full approval to Leqembi, a groundbreaking drug slowing disease progression
USA —The U.S. Food and Drug Administration (FDA) has granted traditional full approval to Leqembi,...
Read More
Biogen shareholders embrace change with election of new board member
USA —Biogen, a leading biotechnology company, has undergone a significant shift in its board of...
Read More
Biogen’s boardroom harmony takes shape as three directors step down
USA — Biogen, a renowned biotechnology company, has announced significant changes to its board of...
Read More
Biogen contemplates legal action following Merck’s lawsuit against US Medicare drug pricing
USA —Biogen CEO Chris Viehbacher has expressed his intention to explore the possibility of taking...
Read More
Biogen continues restructuring, cuts Multiple Sclerosis team
USA — Biogen has laid off an undisclosed number of employees, including members of its multiple...
Read More
EMA accepts Biogen’s marketing authorization for tofersen to treat ALS
NETHERLANDS —The European Medicines Agency (EMA) has accepted the Marketing Authorization...
Read More
LATEST DIGITAL MAGAZINE
